
|Articles|April 15, 2005
A drug with few side effects can cure multiple ills
When I was a boy, my father mentioned several times how he might have purchased IBM stock decades earlier, and how much such an investment would have been worth at the time. Often, people tell me how they refrained from purchasing a waterfront home because the price seemed way too steep, only to have the value subsequently shoot up 10-fold. Perhaps we all regret not making certain purchases long ago.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease
2
FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
3
Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
4
Study shows significant ocular changes following hemodialysis
5














































